Compare iShares Self-Driving EV and Tech (IDRV) vs Johnson & Johnson (JNJ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Self-Driving EV and Tech vs Johnson & Johnson — how do they compare? iShares Self-Driving EV and Tech trades at $36.06, while Johnson & Johnson trades at $255.97 (market cap $603.27B). The key difference: Johnson & Johnson pays a 2.14% dividend while iShares Self-Driving EV and Tech pays none, and Johnson & Johnson is trading nearer its 52-week high, iShares Self-Driving EV and Tech nearer its low. Which is the better fit depends on your goals.
| IDRV | JNJ | |
|---|---|---|
Sector | Sector/Thematic | Health |
52-Week High | $45.48 | $267.24 |
52-Week Low | $32.13 | $164.74 |
Market Cap | — | $603.27B |
Volume | — | 6,156,228 |
Enterprise Value | — | $636.21B |
Dividend Yield | — | 2.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDRV trades at $35.67, down 1.22% for the day, with a bearish technical signal from moving averages and oscillators. The stock faces resistance near $36 and support at $35. Recent news highlights strong global EV sales growth and China's expanding market ambitions, though U.S. adoption lags. A dividend of $0.30 is scheduled for June 2026.
The outlook for IDRV is clouded by technical weakness and competitive pressures, but long-term EV adoption trends offer potential. Key risks include regulatory hurdles and market volatility. Investors should weigh the bearish signals against sector growth catalysts.
Johnson & Johnson (JNJ) trades at $250.61, down 0.96% on the day, with a bullish technical signal and strong fundamental performance. Recent Q2 2026 earnings beat expectations with EPS of $2.90 versus $2.84 expected, and revenue growth of 6.6% year-over-year. The stock shows robust profitability with a net income margin of 21.48% and ROE of 26.42%, supported by consistent dividend payments including the recent $1.34 per share declared for H1-2026.
JNJ presents a favorable investment case with analyst consensus price target of $279.33 implying ~11% upside, though rising debt-to-asset ratio to 24.06% in 2025 and volatile cash flow trends pose risks. The healthcare giant's diversified portfolio and raised full-year guidance underpin long-term stability, but investors should monitor execution amid competitive and regulatory pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Self-Driving EV and Tech
IDRV invests in global companies at the forefront of self-driving and electric vehicle innovation. It provides exposure to the full EV value chain, including battery technology and autonomous systems, with top holdings like Albemarle, Rivian, and Tesla.
Read more on IDRV →About Johnson & Johnson
Johnson & Johnson manufactures health care products and provides related services for the consumer, pharmaceutical, and medical devices and diagnostics markets. The Company sells products such as skin and hair care products, acetaminophen products, pharmaceuticals, diagnostic equipment, and surgical equipment in countries located around the world.
Read more on JNJ →
